Drug Database
Back to search

Switzerland· 67072001

Erleada

A apalutamide product containing apalutamidum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L02BB05

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedErleadaATCL02BB05REGISTER NO.67072001PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about apalutamidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Apalutamide is registered in 15 of 19 countries.

Countries holding a registration under ATC L02BB05 (apalutamide), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 9 of them publish a price we can compare per daily dose
Search apalutamide products by name

Apalutamide · ATC L02BB05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apalutamide costs, country by country.

Normalised to the WHO defined daily dose (0.24 g), the median price runs from $0.094 in France to $370.27 in Switzerland — a ×3935 gap.

  • Switzerland: $370.27 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Apalutamide · price per daily dose (0.24 g)

USD · FX 28 Sept 2026

  • CH Switzerland$370.27
  • FR France$0.094
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
apalutamidum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L02BB05
ATC class
Apalutamide
Defined daily dose
0.24 g, O
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680670720014
    4 Blist 28 Stk
    CHF 2866

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

670 interactions on record for apalutamide.

Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check apalutamide against other medicinesHow interaction checks work

Apalutamide · interactions on record

670 records

  • 244 severe
  • 412 moderate
  • 14 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • RolapitantA04AD14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apalutamide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apalutamide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Erleada
  • Liechtenstein · Erleada
  • Norway · Erleada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7cca4e7d-940e-4d56-aacf-a1533d64bee9
GET /v1/drugs/7cca4e7d-940e-4d56-aacf-a1533d64bee9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "apalutamidum 60 mg",
  "valid_from": "2025-11-01",
  "limitations": "[{\"description\":\"Nach Kostengutsprache des Krankenversicherers mit vorgängiger Konsultation des Vertrauensarztes.<br>\\nERLEADA wird vergütet in Kombination mit Androgendeprivationstherapie (ADT) für die Behandlung von erwachsenen Patienten mit metastasiertem, hormonsensitivem Prostatakarzinom (mHSPC).<br>\\n<br>\",\"costApproval\":null,\"indication\":\"20901.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-11-01\",\"validTo\":\"2028-10-31\"}]",
  "galenic_form": "Filmtabl 60 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2020-11-01",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about apalutamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console